Core Insights - The establishment of the ETHK building by Huajian Medical marks a significant milestone in the development of Real World Asset (RWA) digital technology, positioning Nanjing as a global hub for RWA technology [1][2] - Huajian Medical's strategy focuses on transforming into a digital infrastructure provider, with the ETHK building serving as a physical manifestation of this strategy [2][3] Group 1: RWA Technology and Nanjing Hub - RWA, or Real World Asset tokenization, is emerging as a hot area in global fintech, with a projected total locked value (TVL) of $12.5 billion by June 2025, representing a 124% increase from 2024 [2] - The establishment of ETHK Inc. and ETHK HOLDINGS LIMITED indicates Huajian Medical's commitment to the digital industry infrastructure [2] - Nanjing's location is strategic, as the Yangtze River Delta is a core area for China's biopharmaceutical industry, accounting for one-third of the national industry scale [2] Group 2: Strategic Collaborations - Huajian Medical signed strategic cooperation agreements with four companies, including a $1.5 billion RWA tokenization deal with Chuangsheng Group for six innovative drug pipeline assets [4][7] - The collaboration with Chuangsheng Group aims to integrate their innovative drug assets into a U.S. entity for potential RWA tokenization [4] - Additional partnerships with Shenzhen Yuanli Life Sciences, Jiangsu Mailian Technology, and Beijing Guofeng Law Firm create a comprehensive ecosystem from biopharmaceutical innovation to legal compliance [7] Group 3: Industry Transformation and Market Potential - The launch of the RWA technology base and strategic partnerships signify the scaling of Huajian Medical's ETHK chain financial ecosystem [8] - The global RWA market is projected to reach $16.1 trillion by 2030, representing 10% of global GDP [8] - RWA tokenization in the biopharmaceutical sector allows for the early locking of R&D value, providing new funding channels without equity dilution [8][9] Group 4: Altruistic Ecosystem and New Economic Paradigm - Huajian Medical's "altruistic" approach enables partners to optimize asset structures and innovate financing models [9] - The ETHK building's opening symbolizes a new economic paradigm, enhancing asset liquidity and capital allocation efficiency [10] - The digital economy wave signifies the beginning of a new era for global asset circulation in China [10]

Group 1 - The establishment of the ETHK building marks a significant milestone for the company, representing the physical realization of its ETHK blockchain financial ecosystem strategy and positioning Nanjing as a global hub for Real World Asset (RWA) technology [1][4][14] - The RWA sector is transitioning from concept validation to large-scale application, with a projected total value locked (TVL) of $12.5 billion by June 2025, reflecting a 124% increase from 2024 [4] - The ETHK building will serve as a core base for RWA digital technology research and ecosystem empowerment, housing over 5,000 technical experts and various research facilities [7][14] Group 2 - The company has signed strategic cooperation agreements with four enterprises, including a $1.5 billion RWA tokenization deal with Chuangsheng Group, integrating six core innovative drug pipeline assets into its U.S. entity [8][13] - The partnerships aim to create a comprehensive ecosystem from biopharmaceutical innovation to legal compliance, enhancing the efficiency of asset value discovery and circulation through digitalization [13][14] - The company's "so-in-so" model aims to build a top-tier global trading ecosystem for RWA across multiple industries, providing a one-stop solution for asset digital transformation [13][14] Group 3 - The launch of the ETHK building and the strategic partnerships signify the company's transition into a scalable phase of its ETHK blockchain financial ecosystem strategy [14][15] - The RWA tokenization path chosen by the company is seen as forward-looking, with predictions estimating the global RWA market to reach $16.1 trillion by 2030, accounting for 10% of global GDP [15] - The company's "altruistic" approach allows partners to optimize their asset structures and innovate financing models, facilitating the development of cutting-edge therapies and improving patient accessibility [15][16]

Core Viewpoint - 华检医疗's stock price increased by over 16%, reaching 9.64 HKD, with a trading volume of 29.15 million HKD, following the announcement of a board meeting scheduled for August 29, 2025, to discuss mid-term performance and potential dividend payments [1] Group 1 - The company has launched several key strategic initiatives since late July, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [1] - The company is pushing its U.S. subsidiary to apply for a stablecoin license and has partnered with BGI's subsidiary to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [1] - On August 8, the company announced the launch of a "Global Enhanced Ethereum (ETH) Treasury" strategy and completed the compliant purchase of 149 million HKD in ETH in collaboration with licensed exchange HashKey [1] Group 2 - The company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the medical innovative drug RWA trading platform ecosystem [1]

Core Viewpoint - Huajian Medical (01931) has seen a significant stock price increase, rising over 16% in the afternoon trading session, attributed to strategic initiatives and upcoming financial announcements [1] Group 1: Stock Performance - As of the latest update, Huajian Medical's stock price is reported at 9.64 HKD, with a trading volume of 29.1585 million HKD [1] Group 2: Strategic Initiatives - The company announced a board meeting scheduled for August 29, 2025, to consider and approve the mid-term performance for the six months ending June 30, 2025, and to discuss potential interim dividends [1] - Since late July, Huajian Medical has launched several key strategic initiatives, including the introduction of the "NewCo+RWA" exchange strategy and the issuance of IVDD stablecoins [1] - The company is pushing its U.S. subsidiary to apply for a stablecoin license and has partnered with BGI's subsidiary to establish the world's first "Innovative Drug Intellectual Property Tokenization Fund" [1] - On August 8, Huajian Medical officially launched the "Global Enhanced Ethereum (ETH) Treasury" strategy, collaborating with the licensed exchange HashKey and completing a compliant purchase of 149 million HKD in ETH [1] - Recently, the company is seeking shareholder approval for a 3 billion HKD ETH purchase authorization to provide value anchoring and revenue feedback mechanisms for the medical innovation drug RWA trading platform [1]

Group 1 - BlackRock invested over $1.2 billion in ETH, significantly outpacing its $267 million investment in BTC, indicating a shift in Wall Street's capital direction from Bitcoin as "digital gold" to Ethereum as "digital oil" [1] - The rapid growth of BlackRock's Ethereum ETF (ETHA) from $5 billion to over $10 billion in just 10 days reflects changing investor sentiment towards Ethereum [1] Group 2 - Huajian Medical announced its transformation into the first enhanced Ethereum treasury company in Hong Kong, marking a strategic advancement in the market [2] - The company initiated a global enhanced Ethereum treasury strategy with a multi-layered "downside protection" mechanism and active "yield enhancement" strategies [3] Group 3 - Huajian Medical partnered with HashKey Group to establish a compliant trading channel for large-scale ETH transactions and to explore the integration of crypto assets with real-world assets (RWA) [6] - The company approved the purchase of 5,190 ETH at an average price of HKD 28,798.21, totaling HKD 149 million, as a significant step in its treasury strategy [7] Group 4 - Wall Street's consensus indicates that Ethereum is becoming a necessary asset for institutional investment, supported by five core value pillars including its deflationary nature and yield generation capabilities [8][9] - Ethereum's role as a foundational settlement asset in the DeFi ecosystem positions it as a preferred choice for RWA tokenization and stablecoin issuance [9] Group 5 - Huajian Medical's Ethereum treasury strategy is closely linked to its core business of medical RWA tokenization, aiming to create a unique ecosystem for innovative drug assets [10] - The company's ivd.xyz exchange is designed to facilitate the issuance and trading of medical RWA, integrating Ethereum as a core asset for governance and liquidity [10] Group 6 - The treasury strategy includes an "insurance mechanism" to mitigate volatility risks and a systematic investment approach to smooth costs [13][14] - Huajian Medical aims to address the challenges in innovative drug development financing through its tokenization strategy, enhancing investment efficiency [15] Group 7 - The market is recognizing the potential for Huajian Medical's treasury model to achieve significant valuation, drawing parallels to MicroStrategy's success with Bitcoin [17] - The company's stock price surged by 118% in July and 38.43% on August 6, indicating strong market interest and potential for value discovery [19] Group 8 - Huajian Medical's strategic vision includes applying for stablecoin licenses in both Hong Kong and the U.S., aiming to connect innovative drug assets with global capital through the Ethereum ecosystem [24] - The company's ambition is to leverage Ethereum's properties to create a new benchmark in the Hong Kong market, facilitating the global circulation of Chinese biomedical assets [24]